Metronidazol Hikma (Metronidazole)

Metronidazole enters anaerobic cells and is reduced to reactive nitro radicals. These radicals damage DNA and inhibit nucleic acid synthesis, leading to cell death. The selective activation in low‑oxygen environments provides targeted antimicrobial activity against susceptible anaerobes and protozoa.

The dosage of Metronidazol Hikma is determined by the prescribing clinician based on the specific infection, patient weight, renal and hepatic function, and other clinical factors. Only a qualified health professional should set the dosing regimen.

Safety data for metronidazole in pregnancy are limited, and the product is classified as pregnancy category unknown. It should only be used when the potential benefit justifies any potential risk to the fetus. Breastfeeding mothers should consult their physician, as the drug can be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Metronidazole is a nitroimidazole that specifically targets anaerobic organisms, offering rapid bactericidal activity. Compared with broad‑spectrum agents like clindamycin, metronidazole often has fewer drug‑interaction concerns and a well‑established efficacy profile for anaerobic and protozoal infections, though choice depends on pathogen susceptibility and patient factors.

Metronidazol Hikma should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperatures to maintain stability and potency.

Metronidazol Hikma is supplied as an injectable solution for intravenous infusion. Administration is performed by qualified healthcare personnel in a clinical setting, following aseptic technique and the dosing instructions provided by the prescriber.

Serious risks include seizures, peripheral neuropathy, and severe allergic reactions such as anaphylaxis. Patients should be monitored for neurologic symptoms, skin reactions, and any signs of hypersensitivity, and treatment should be discontinued if these events occur.

Metronidazol Hikma is contraindicated in patients with a known hypersensitivity to metronidazole or other nitroimidazole derivatives. Caution is also advised for individuals with severe hepatic impairment, and it should be avoided in patients who have consumed alcohol within 48 hours of dosing.